denotes an abstract that is clinically relevant.
denotes that this is a recommended PHD Trainee Session.
denotes that this is a ticketed session.Hematology Disease Topics & Pathways:
Diseases, Non-Biological, CMML, Therapies, chemotherapy, MPN, Polycythemia vera, thrombocythemia, Clinically relevant, Myeloid Malignancies
Description:
The genomic revolution has transformed our understanding of the pathophysiology of the myeloproliferative neoplasms (MPN), and has redefined MPN diagnostic criteria. The myeloproliferative neoplasms are indolent diseases where survival is measured in decades, yet morbidity and mortality vary widely. In addition to transforming diagnostic criteria, genomics have informed nearly every aspect of MPN. This educational session will explore the evidence for comprehensive genomic assessment during stages of MPN from initial evaluation, through evolution and transformation.
Dr. Alison Moliterno will outline the evidence for use of genomic testing in evaluating MPN presentation across varied clinical contexts. She will discuss the evidence supporting the use of clonal genomic burden in determining MPN subtypes and assessing thrombosis risk, and its use in clinical decision making.
Dr. Olatoyosi Odenike will discuss how genomics informs the evaluation and management of MPN progression. The therapies for MPN have expanded, and the genomics of clonal progression and transformation can be a guiding light in assessing suitability for therapies to meet treatment goals.
Dr. Mrinal Patnaik will discuss the opportunities and challenges that genomics offers in the management of myeloproliferative/myelodysplastic syndromes. He will discuss the insights that genomics has produced in illuminating these complex syndromes, and will highlight how genomic assessment will light the way to targeted therapy.
Dr. Alison Moliterno will outline the evidence for use of genomic testing in evaluating MPN presentation across varied clinical contexts. She will discuss the evidence supporting the use of clonal genomic burden in determining MPN subtypes and assessing thrombosis risk, and its use in clinical decision making.
Dr. Olatoyosi Odenike will discuss how genomics informs the evaluation and management of MPN progression. The therapies for MPN have expanded, and the genomics of clonal progression and transformation can be a guiding light in assessing suitability for therapies to meet treatment goals.
Dr. Mrinal Patnaik will discuss the opportunities and challenges that genomics offers in the management of myeloproliferative/myelodysplastic syndromes. He will discuss the insights that genomics has produced in illuminating these complex syndromes, and will highlight how genomic assessment will light the way to targeted therapy.